CASE REPORT: THE POSSIBILITY OF SPECIFIC THERAPY OPTIMIZATION BY SWITCHING FROM BOSENTAN TO MACITENTAN IN A PATIENT WITH CONGENITAL HEART DISEASE AND EISENMENGER SYNDROME

CASE REPORT: THE POSSIBILITY OF SPECIFIC THERAPY OPTIMIZATION BY SWITCHING FROM BOSENTAN TO MACITENTAN IN A PATIENT WITH CONGENITAL HEART DISEASE AND EISENMENGER SYNDROME

A patient with pulmonary arterial hypertension (PAH) associated with congenital heart disease (ventricular septal defect) and Eisenmenger syndrome was started on an endothelin receptor antagonist bosentan. With treatment, the patient's condition had been stable, however, by the second year, wor...

Full description

Saved in:
Bibliographic Details
Main Authors: S. Ye. Gratsianakaya, O. A. Arkhipova, A. I. Davydov, T. V. Martynyuk, N. A. Ananicheva, O. S. Belkorey, I. Ye. Chazova
Format: Article
Language:Russian
Published: InterMedservice 2018-03-01
Series:Евразийский Кардиологический Журнал
Subjects:
eisenmenger syndrome
macitentan
Online Access:https://www.heartj.asia/jour/article/view/277
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items